Common use
Daliresp (roflumilast) is a prescription PDE4 inhibitor specifically designed for the long-term management of chronic obstructive pulmonary disease (COPD). If you are looking to buy Daliresp online for COPD treatment, it is important to understand how this respiratory medication works. Roflumilast targets phosphodiesterase-4 enzymes in the lungs, delivering a powerful anti-inflammatory effect that helps reduce the frequency and severity of COPD exacerbations. This medication is particularly beneficial for patients with severe COPD associated with chronic bronchitis who experience frequent flare-ups despite using other maintenance therapies. By decreasing airway inflammation at the cellular level, Daliresp helps improve lung function and supports better breathing over time, making it a valuable addition to a comprehensive exacerbation prevention strategy.

Dosage and direction
Take Daliresp orally once daily, with or without food, exactly as prescribed by your doctor. The standard dose of roflumilast is one 500 mcg tablet per day. Swallow the tablet whole with a full glass of water, and take it at the same time each day for best results and consistent therapeutic levels. Do not crush, chew, or break the tablet. Some healthcare providers may recommend starting at a lower dose initially to help your body adjust and minimize gastrointestinal side effects. It may take several weeks of consistent use before you notice the full benefits of this COPD treatment, so patience and adherence to your prescribed regimen are essential.

Precautions
Before you buy roflumilast or begin treatment with Daliresp, inform your doctor about your complete medical history. This is especially important if you have liver disease, depression, anxiety, or a history of suicidal thoughts or other mental health conditions. Weight loss is a commonly reported effect during treatment with this PDE4 inhibitor, so regular monitoring of body weight is recommended. Mood changes, including feelings of sadness, irritability, or unusual behavior, may occur and should be reported to your healthcare provider immediately. Patients should also disclose any history of insomnia or sleep disturbances, as roflumilast may affect sleep quality. Regular follow-up appointments are essential to monitor your respiratory health and overall well-being throughout the course of therapy.

Contraindications
Do not use Daliresp if you have moderate to severe liver impairment (Child-Pugh B or C classification), as roflumilast is extensively metabolized by the liver and impaired hepatic function can lead to dangerously elevated drug levels. This medication is not intended for the relief of acute bronchospasm or as a rescue therapy during sudden COPD attacks. Daliresp is contraindicated in individuals with known hypersensitivity to roflumilast or any inactive ingredient in the formulation. Patients who are pregnant or planning to become pregnant should avoid this medication, as its safety during pregnancy has not been established.

Possible side effect
Common side effects of Daliresp include diarrhea, nausea, reduced appetite, weight loss, headache, back pain, and insomnia. Diarrhea and nausea are most frequently reported during the initial weeks of treatment and often diminish as your body adjusts to the medication. More serious but less common side effects may involve significant mood changes, new or worsening depression, anxiety, or in rare cases, suicidal thoughts or behavior. If you experience any psychiatric symptoms, discontinue use and seek immediate medical attention. Other rare adverse reactions include tremor, palpitations, and allergic skin reactions such as rash or urticaria.

Drug interaction
Roflumilast is metabolized primarily through the CYP3A4 and CYP1A2 enzyme pathways, making it susceptible to significant drug interactions. Strong CYP3A4 inhibitors such as ketoconazole, itraconazole, and ritonavir can increase roflumilast exposure and may require dose adjustments. Conversely, CYP3A4 inducers such as rifampin, phenobarbital, carbamazepine, and phenytoin can substantially reduce the effectiveness of this PDE4 inhibitor. Concurrent use with theophylline is not recommended due to potential increased side effects. Always inform your doctor and pharmacist about all prescription medications, over-the-counter drugs, and herbal supplements you are taking before starting Daliresp to avoid potentially harmful interactions.

Missed dose
If you miss a dose of Daliresp, take it as soon as you remember on the same day. If it is nearly time for your next scheduled dose, skip the missed one and resume your regular dosing schedule. Do not take two doses at once or double up to compensate for a missed dose, as this may increase the risk of side effects without providing additional therapeutic benefit.

Overdose
Symptoms of roflumilast overdose may include severe nausea, vomiting, headache, dizziness, palpitations, and significant mental or mood changes. There is no specific antidote for Daliresp overdose. In such cases, seek emergency medical assistance immediately and provide information about the amount ingested and the time of ingestion. Supportive care and symptomatic treatment will be administered as needed under medical supervision.

Storage
Store Daliresp at controlled room temperature between 20°C and 25°C (68°F to 77°F), away from excessive heat, moisture, and direct sunlight. Keep the tablets in their original container with the lid tightly closed, and store out of reach of children and pets. Do not use the medication after the expiration date printed on the packaging, and dispose of any expired or unused tablets in accordance with local pharmaceutical waste guidelines.

Disclaimer

We provide only general information about medications which does not cover all directions, possible drug integrations, or precautions. Information at the site cannot be used for self-treatment and self-diagnosis. Any specific instructions for a particular patient should be agreed with your health care adviser or doctor in charge of the case. We disclaim reliability of this information and mistakes it could contain. We are not responsible for any direct, indirect, special or other indirect damage as a result of any use of the information on this site and also for consequences of self-treatment.